Genome-scale screens identify JNK–JUN signaling as a barrier for pluripotency exit and endoderm differentiation

Human embryonic stem cells (ESCs) and human induced pluripotent stem cells hold great promise for cell-based therapies and drug discovery. However, homogeneous differentiation remains a major challenge, highlighting the need for understanding developmental mechanisms. We performed genome-scale CRISP...

Full description

Saved in:
Bibliographic Details
Published inNature genetics Vol. 51; no. 6; pp. 999 - 1010
Main Authors Li, Qing V., Dixon, Gary, Verma, Nipun, Rosen, Bess P., Gordillo, Miriam, Luo, Renhe, Xu, Chunlong, Wang, Qiong, Soh, Chew-Li, Yang, Dapeng, Crespo, Miguel, Shukla, Abhijit, Xiang, Qing, Dündar, Friederike, Zumbo, Paul, Witkin, Matthew, Koche, Richard, Betel, Doron, Chen, Shuibing, Massagué, Joan, Garippa, Ralph, Evans, Todd, Beer, Michael A., Huangfu, Danwei
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.06.2019
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human embryonic stem cells (ESCs) and human induced pluripotent stem cells hold great promise for cell-based therapies and drug discovery. However, homogeneous differentiation remains a major challenge, highlighting the need for understanding developmental mechanisms. We performed genome-scale CRISPR screens to uncover regulators of definitive endoderm (DE) differentiation, which unexpectedly uncovered five Jun N-terminal kinase (JNK)–JUN family genes as key barriers of DE differentiation. The JNK–JUN pathway does not act through directly inhibiting the DE enhancers. Instead, JUN co-occupies ESC enhancers with OCT4, NANOG, SMAD2 and SMAD3, and specifically inhibits the exit from the pluripotent state by impeding the decommissioning of ESC enhancers and inhibiting the reconfiguration of SMAD2 and SMAD3 chromatin binding from ESC to DE enhancers. Therefore, the JNK–JUN pathway safeguards pluripotency from precocious DE differentiation. Direct pharmacological inhibition of JNK significantly improves the efficiencies of generating DE and DE-derived pancreatic and lung progenitor cells, highlighting the potential of harnessing the knowledge from developmental studies for regenerative medicine. CRISPR screens identify JNK–JUN family genes as repressors of definitive endoderm differentiation in human pluripotent stem cells. JUN co-occupies stem cell enhancers with OCT4, NANOG, SMAD2 and SMAD3 and inhibits the exit from pluripotency.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Q.V.L. and D.H. designed experiments, analyzed and interpreted results. Q.V.L. performed most experiments. M.A.B. performed the mathematical modeling and computational analysis. G.D., B.P.R., R.L. and A.S. assisted with the screen and the validation experiments. N.V. performed neuroectoderm differentiation experiments. Q.X. and R.G. provided assistance related to the CRISPR library construction and sequencing. Q.W. and J.M. provided protocols, reagents and technical support on experiments related to ChIP-seq and TGF-β signaling. M.W. and R.K. assisted with ATAC-seq and ChIP-seq experiments. C.-L.S., D.Y., M.G., C.X., M.C., S.C. and T.E. tested JNK inhibitors and assisted with additional experiments and data analyses. F.D., P.Z. and D.B. performed Drop-seq data analysis. Q.V.L., M.A.B. and D.H. wrote the manuscript and all other authors provided editorial advice.
Author Contributions
ISSN:1061-4036
1546-1718
DOI:10.1038/s41588-019-0408-9